Evidence map›Paper›PMID 42368972›Full record

Trial reportCancer communications (London, England)2026

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.

Lina Zhang, Jingxuan Wang, Tao Sun, Fanfan Li, Bing Zhao, Guohui Han, Zhongsheng Tong, Hua Yang, Yongmei Yin, Xiangshun Kong and 34 more

Abstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Lina ZhangBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Jingxuan WangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
Tao SunDepartment of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.
Fanfan LiDepartment of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
Bing ZhaoDepartment of Medical Oncology, Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, Xinjiang, P. R. China.
Guohui HanDepartment of Medical Oncology, Shanxi Cancer Hospital, Taiyuan, Shanxi, P. R. China.
Zhongsheng TongDepartment of Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, P. R. China.
Hua YangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei, P. R. China.
Yongmei YinDepartment of Oncology, Jiangsu Province Hospital, Nanjing, Jiangsu, P. R. China.
Xiangshun KongDepartment of Breast Surgery, Xingtai People's Hospital, Xingtai, Hebei, P. R. China.
Ying WangDepartment of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Jianyun NieDepartment of Breast Surgery, Yunnan Cancer Hospital, Kunming, Yunnan, P. R. China.
Lixia MaDepartment of Medical Oncology, Jilin Cancer Hospital, Changchun, Jilin, P. R. China.
Yongqiang ZhangDepartment of Medical Oncology, Beijing Hospital, Beijing, P. R. China.
Jing LuoDepartment of Breast Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan, P. R. China.
Changping ShanDepartment of Medical Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, P. R. China.
Jing YaoCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
Shisheng TanDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, P. R. China.
Xiaoling LingDepartment of Medical Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, P. R. China.
Hongmei SunDepartment of Oncology, Jiamusi Tumor Tuberculosis Hospital, Jiamusi, Heilongjiang, P. R. China.
Huihui LiDepartment of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
Li MaBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Tao ZhouBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Yunjiang LiuBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Yixin QiBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Zhenchuan SongBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Yuntao LiBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Chao YangBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Tianli HuiBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Meiqi WangBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Haoqi WangBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Xi ZhangBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
Wenhui ZhaoDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
Yanhui LiClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Mengmeng LiClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Ying XinClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Xuan LuoClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Deliang YinClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Hongmei LuoClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Huan LiuClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Qianyun LuClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Jing YuanClinical Development Division, CSPC Ouyi Pharmaceutical Technology Co., Ltd., Shijiazhuang, Hebei, P. R. China.
Qingyuan ZhangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
Cuizhi GengBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.ORCID https://orcid.org/0000-0001-5541-5412

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Albumin-Bound PaclitaxelAntineoplastic Agents, PhytogenicBreast NeoplasmsPaclitaxelAdultAgedDouble-Blind MethodFemaleHumansMiddle AgedAlbumin-Bound PaclitaxelAntineoplastic Agents, PhytogenicPaclitaxel

Identifiers

PMID42368972
PMCPMC13305025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.